newsfilter
← Latest News
GlobeNewswire·

Morphic Announces Corporate Highlights and Financial Results for the Full Year 2023

-Reported positive results from EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis (UC)- -Enrollment on target in EMERALD-2 phase 2b global randomized trial of MORF-057 in UC-